Photo from wikipedia
Multiple myeloma accounts for over 10–15% of haematological malignancies. Continued molecular advances have resulted in the development of new drugs for treatment of multiple myeloma. Four drugs were approved by… Click to show full abstract
Multiple myeloma accounts for over 10–15% of haematological malignancies. Continued molecular advances have resulted in the development of new drugs for treatment of multiple myeloma. Four drugs were approved by the Food and Drug Administration (FDA) in 2015, but their safety is not well defined. The aim of this study is to delineate the cardiovascular adverse events of these drugs.
Keywords:
complications modern;
modern multiple;
myeloma;
cardiovascular complications;
multiple myeloma;
study
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!